Strength training and aerobic exercise training for muscle disease

Autor:	Nicoline B M Voet, Baziel G.M. van Engelen, Ingrid I. Riphagen, Eline Lindeman, Alexander C. H. Geurts, Elly van der Kooi
Rok vydání:	2019
Předmět:	medicine.medical_specialty Strength training education Physical fitness Polymyositis Dermatomyositis Muscular Dystrophies Physical medicine and rehabilitation Muscular Diseases medicine Humans Myotonic Dystrophy Facioscapulohumeral muscular dystrophy Aerobic exercise Pharmacology (medical) Muscle Strength Exercise physiology Exercise Randomized Controlled Trials as Topic Human Movement & Fatigue [NCEBP 10] Exercise Tolerance business.industry Mitochondrial Myopathies Resistance Training Cardiorespiratory fitness medicine.disease Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] Muscular Dystrophy Facioscapulohumeral Human Movement & Fatigue DCN PAC - Perception action and control [NCEBP 10] Human Movement & Fatigue [DCN MP - Plasticity and memory NCEBP 10] Physical Fitness Physical therapy business Functional Neurogenomics [DCN 2]
Zdroj:	Cochrane Database of Systematic Reviews, 12, pp. Cd003907 The Cochrane Library Cochrane Database of Systematic Reviews, 1, pp. CD003907-CD003907 Cochrane Database of Systematic Reviews, 7, 7, pp. CD003907 Cochrane Database of Systematic Reviews, 12, Cd003907 Cochrane Database Syst Rev Cochrane Database of Systematic Reviews, 7, CD003907 Cochrane Database of Systematic Reviews, CD003907-CD003907 STARTPAGE=CD003907;ENDPAGE=CD003907;ISSN=1469-493X;TITLE=Cochrane Database of Systematic Reviews
ISSN:	1469-493X
Popis:	BACKGROUND: Strength training or aerobic exercise programmes, or both, might optimise muscle and cardiorespiratory function and prevent additional disuse atrophy and deconditioning in people with a muscle disease. This is an update of a review first published in 2004 and last updated in 2013. We undertook an update to incorporate new evidence in this active area of research. OBJECTIVES: To assess the effects (benefits and harms) of strength training and aerobic exercise training in people with a muscle disease. SEARCH METHODS: We searched Cochrane Neuromuscular's Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL in November 2018 and clinical trials registries in December 2018. SELECTION CRITERIA: Randomised controlled trials (RCTs), quasi‐RCTs or cross‐over RCTs comparing strength or aerobic exercise training, or both lasting at least six weeks, to no training in people with a well‐described muscle disease diagnosis. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 14 trials of aerobic exercise, strength training, or both, with an exercise duration of eight to 52 weeks, which included 428 participants with facioscapulohumeral muscular dystrophy (FSHD), dermatomyositis, polymyositis, mitochondrial myopathy, Duchenne muscular dystrophy (DMD), or myotonic dystrophy. Risk of bias was variable, as blinding of participants was not possible, some trials did not blind outcome assessors, and some did not use an intention‐to‐treat analysis. Strength training compared to no training (3 trials) For participants with FSHD (35 participants), there was low‐certainty evidence of little or no effect on dynamic strength of elbow flexors (MD 1.2 kgF, 95% CI −0.2 to 2.6), on isometric strength of elbow flexors (MD 0.5 kgF, 95% CI −0.7 to 1.8), and ankle dorsiflexors (MD 0.4 kgF, 95% CI −2.4 to 3.2), and on dynamic strength of ankle dorsiflexors (MD −0.4 kgF, 95% CI −2.3 to 1.4). For participants with myotonic dystrophy type 1 (35 participants), there was very low‐certainty evidence of a slight improvement in isometric wrist extensor strength (MD 8.0 N, 95% CI 0.7 to 15.3) and of little or no effect on hand grip force (MD 6.0 N, 95% CI −6.7 to 18.7), pinch grip force (MD 1.0 N, 95% CI −3.3 to 5.3) and isometric wrist flexor force (MD 7.0 N, 95% CI −3.4 to 17.4). Aerobic exercise training compared to no training (5 trials) For participants with DMD there was very low‐certainty evidence regarding the number of leg revolutions (MD 14.0, 95% CI −89.0 to 117.0; 23 participants) or arm revolutions (MD 34.8, 95% CI −68.2 to 137.8; 23 participants), during an assisted six‐minute cycle test, and very low‐certainty evidence regarding muscle strength (MD 1.7, 95% CI −1.9 to 5.3; 15 participants). For participants with FSHD, there was low‐certainty evidence of improvement in aerobic capacity (MD 1.1 L/min, 95% CI 0.4 to 1.8, 38 participants) and of little or no effect on knee extension strength (MD 0.1 kg, 95% CI −0.7 to 0.9, 52 participants). For participants with dermatomyositis and polymyositis (14 participants), there was very low‐certainty evidence regarding aerobic capacity (MD 14.6, 95% CI −1.0 to 30.2). Combined aerobic exercise and strength training compared to no training (6 trials) For participants with juvenile dermatomyositis (26 participants) there was low‐certainty evidence of an improvement in knee extensor strength on the right (MD 36.0 N, 95% CI 25.0 to 47.1) and left (MD 17 N 95% CI 0.5 to 33.5), but low‐certainty evidence of little or no effect on maximum force of hip flexors on the right (MD −9.0 N, 95% CI −22.4 to 4.4) or left (MD 6.0 N, 95% CI −6.6 to 18.6). This trial also provided low‐certainty evidence of a slight decrease of aerobic capacity (MD −1.2 min, 95% CI −1.6 to 0.9). For participants with dermatomyositis and polymyositis (21 participants), we found very low‐certainty evidence for slight increases in muscle strength as measured by dynamic strength of knee extensors on the right (MD 2.5 kg, 95% CI 1.8 to 3.3) and on the left (MD 2.7 kg, 95% CI 2.0 to 3.4) and no clear effect in isometric muscle strength of eight different muscles (MD 1.0, 95% CI −1.1 to 3.1). There was very low‐certainty evidence that there may be an increase in aerobic capacity, as measured with time to exhaustion in an incremental cycle test (17.5 min, 95% CI 8.0 to 27.0) and power performed at VO(2) max (maximal oxygen uptake) (18 W, 95% CI 15.0 to 21.0). For participants with mitochondrial myopathy (18 participants), we found very low‐certainty evidence regarding shoulder muscle (MD −5.0 kg, 95% CI −14.7 to 4.7), pectoralis major muscle (MD 6.4 kg, 95% CI −2.9 to 15.7), and anterior arm muscle strength (MD 7.3 kg, 95% CI −2.9 to 17.5). We found very low‐certainty evidence regarding aerobic capacity, as measured with mean time cycled (MD 23.7 min, 95% CI 2.6 to 44.8) and mean distance cycled until exhaustion (MD 9.7 km, 95% CI 1.5 to 17.9). One trial in myotonic dystrophy type 1 (35 participants) did not provide data on muscle strength or aerobic capacity following combined training. In this trial, muscle strength deteriorated in one person and one person had worse daytime sleepiness (very low‐certainty evidence). For participants with FSHD (16 participants), we found very low‐certainty evidence regarding muscle strength, aerobic capacity and VO(2) peak; the results were very imprecise. Most trials reported no adverse events other than muscle soreness or joint complaints (low‐ to very low‐certainty evidence). AUTHORS' CONCLUSIONS: The evidence regarding strength training and aerobic exercise interventions remains uncertain. Evidence suggests that strength training alone may have little or no effect, and that aerobic exercise training alone may lead to a possible improvement in aerobic capacity, but only for participants with FSHD. For combined aerobic exercise and strength training, there may be slight increases in muscle strength and aerobic capacity for people with dermatomyositis and polymyositis, and a slight decrease in aerobic capacity and increase in muscle strength for people with juvenile dermatomyositis. More research with robust methodology and greater numbers of participants is still required.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85719a6a2c77965aa06f34ae34a9c8c0 https://hdl.handle.net/2066/215532 Zobrazit plný text záznamu